Literature DB >> 21119147

Treatment adherence in psychoses.

Anthony S David.   

Abstract

A well-conducted randomised controlled trial of an intervention to improve treatment adherence in psychosis published in this issue shows beneficial effects on self- and observer-rated adherence and trends towards fewer hospital readmissions. Partial adherence is the single most important barrier to optimal treatment. National Institute for Health and Clinical Excellence guidelines on adherence need to be revised.

Entities:  

Mesh:

Year:  2010        PMID: 21119147     DOI: 10.1192/bjp.bp.110.083022

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Authors:  Cinzia Niolu; Emanuela Bianciardi; Giorgio Di Lorenzo; Claudia Marchetta; Ylenia Barone; Nicoletta Sterbini; Michele Ribolsi; Giorgio Reggiardo; Alberto Siracusano
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

Review 2.  Appraisal of patient-level health economic models of severe mental illness: systematic review.

Authors:  James Altunkaya; Jung-Seok Lee; Apostolos Tsiachristas; Felicity Waite; Daniel Freeman; José Leal
Journal:  Br J Psychiatry       Date:  2021-08-19       Impact factor: 9.319

3.  Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries.

Authors:  Anita Patel; Paul McCrone; Morven Leese; Francesco Amaddeo; Michele Tansella; Reinhold Kilian; Matthias Angermeyer; Martijn Kikkert; Aart Schene; Martin Knapp
Journal:  Cost Eff Resour Alloc       Date:  2013-05-25

Review 4.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.